Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-22
2010-11-30
Desai, Anand U (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C424S423000
Reexamination Certificate
active
07842667
ABSTRACT:
A method of treating a disorder characterized by tissue damage is provided. The method comprising providing to a subject in need-thereof a composition which comprises a synthetic polymer attached to denatured fibrinogen or a therapeutic portion of the fibrinogen, the composition being formulated for releasing the therapeutic portion of the fibrinogen in a pharmacokinetically regulated manner, thereby treating the disorder characterized by tissue damage or malformation.
REFERENCES:
patent: 4925924 (1990-05-01), Silver et al.
patent: 4970298 (1990-11-01), Silver et al.
patent: 5410016 (1995-04-01), Hubbell et al.
patent: 5529914 (1996-06-01), Hubbell et al.
patent: 5567435 (1996-10-01), Hubbell et al.
patent: 5573934 (1996-11-01), Hubbell et al.
patent: 5626863 (1997-05-01), Hubbell et al.
patent: 5733563 (1998-03-01), Fortier
patent: 5834274 (1998-11-01), Hubbell et al.
patent: 5843743 (1998-12-01), Hubbell et al.
patent: 5858746 (1999-01-01), Hubbell et al.
patent: 5863984 (1999-01-01), Doillon et al.
patent: 5902599 (1999-05-01), Anseth et al.
patent: 5986043 (1999-11-01), Hubbell et al.
patent: 6060582 (2000-05-01), Hubbell et al.
patent: 6153211 (2000-11-01), Hubbell et al.
patent: 6224893 (2001-05-01), Langer et al.
patent: 6306922 (2001-10-01), Hubbell et al.
patent: 6403672 (2002-06-01), Randolph et al.
patent: 6565842 (2003-05-01), Sojomihardjo et al.
patent: 6703037 (2004-03-01), Hubbell et al.
patent: 6858229 (2005-02-01), Hubbell et al.
patent: 6864301 (2005-03-01), Randolph et al.
patent: 6911227 (2005-06-01), Hubbell et al.
patent: 2004/0082511 (2004-04-01), Watzek et al.
patent: 2006/0233854 (2006-10-01), Seliktar et al.
patent: 0605797 (1994-07-01), None
patent: 0976759 (2000-02-01), None
patent: WO 98/32466 (1998-07-01), None
patent: WO 99/34833 (1999-07-01), None
patent: WO 01/53324 (2001-07-01), None
patent: WO 02/018441 (2002-07-01), None
patent: WO 2004/041298 (2004-05-01), None
patent: WO 2005/061018 (2005-07-01), None
Halstenberg et al.,“Biologically Engineered Protein-graft-Poly(ethylene glycol) Hydrogels: A Cell Adhesive and Plasmin-Degradable Biosynthetic Material for Tissue Repair”, Biomacromolecules 3: 710-723 (2002).
Akassoglou et al., “Fibrin Inhibits Peripheral Nerve Remyelination by Regulating Schwann Cell Differentiation”, Neuron 33: 861-875 (2002).
Meyers and Herron, “A Fibrin Adhesive Seal for the Repair of Osteochondral Fracture Fragments”, Clinical Orthopaedics and Related Research, Jan.-Feb. 1984 No. 182 pp. 258-263.
Pluger et al., “Untersuchungen uber das Einwachsen von Knochenge porose Metallimplantate”, Wien Klin. Wochenschr., 91: 482-487 (1979).
Hooftman et al. “Review: Poly(Ethylene Glycol)s With Reactive Endgroups. II. Practical Consideratiion for the Preparation of Protein-PEG Conjugates”, Journal of Bioactive and Compatible Polymers, 11: 135-159, 1996.
Deible et al. “Molecular Barriers to Biomaterial Thrombosis by Modification of Surface Proteins With Polyethylene Glycol”, Biomaterials, 19: 1885-1893, 1998.
Veronese “Peptide and Protein PEGylation: A Review of Problems and Solutions”, Biomaterials, 22: 405-417, 2001.
Li et al. “Synthesis of Polyethylene Glycol (PEG) Derivatives and PEGylated-Peptide Biopolymer Conjugates”, Biomacromolecules, 4: 1055-1067, 2003.
Zalipsky “Chemistry of Polyethylene Glycol Conjugates With Biologically Active Molecules”, Advanced Drug Delivery Reviews, 16: 157-182, 1995.
Almany et al. “Biosynthetic Hydrogel Scaffolds Made From Fibrinogen and Polyethylene Glycol for 3D Cell Cultures”, Biomaterials, 26: 2467-2477, 2005.
Seliktar et al. “MMP-2 Sensitive, VEGF-Bearing Bioactive Hydrogels for Promotion of Vascular Healing”, Journal of Biomedical Materials Research—Part. A, 68(4): 704-716, 2004. Abstract.
Gayet et al. “Drug Release From New Bioartificial Hydrogel”, Art. Cells, Blood Subs., and Immob. Biotech., 23(5): 605-611, 1995.
D'Urso et al. “Poly(Ethylene Glycol)-Serum Albumin Hydrogel as Matrix for Enzyme Immobilization: Biomedical Applications”, Art. Cells, Blood Subs., and Biotech., 23(5): 587-595, 1995.
Dikovsky et al. “The Effect of Structural Alterations of PEG-Fibrinogen Hydrogel Scaffolds on 3-D Cellular Morphology and Cellular Migration”, Biomaterials, 27(8): 1496-1506, 2005. Abstract, p. 1497, § 2.1, 2.2.
International Search Report Dated Aug. 2, 2005 From the International Searching Authority Re.: Application No. PCT/IL2004/001136.
Communication Pursuant to Article 94(3) EPC Dated Jul. 6, 2009 From the European Patent Office Re.: Application No. 04806668.2.
Official Action Dated Feb. 4, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/472,520.
Official Action Dated Sep. 17, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/472,437.
Official Action Dated Jan. 21, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/472,437.
Response Dated Dec. 16, 2009 to Official Action of Sep. 17, 2009 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/472,437.
Response Dated Jan. 28, 2010 to Communication Pursuant to Article 94(3) EPC of Jul. 6, 2009 From the European Patent Office Re.: Application No. 04806668.2.
Response Dated Apr. 21, 2010 to Official Action of Jan. 21, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/472,437.
Official Action Dated Jun. 29, 2010 From the US Patent and Trademark Office Re.: U.S. Appl. No. 11/472,437.
Invitation Pursuant to Article 94(3) and Rule 71(1) EPC Dated Jun. 10, 2010 From the European Patent Office Re. Application No. 04806668.2.
Almany Liora
Seliktar Dror
Desai Anand U
Regentis Biomaterials Ltd.
LandOfFree
Matrix composed of a naturally-occurring protein backbone... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Matrix composed of a naturally-occurring protein backbone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Matrix composed of a naturally-occurring protein backbone... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4218025